Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340581 | 0.86 | DNM1 (0.39) | TSHRSMN1; SMN2CA2MAPK1CA1 | |
| SCHEMBL16599518 | 0.81 | TSHR (0.41) | TSHRSMN1; SMN2CA2MAPK1CA1 | |
| SCHEMBL2346185 | 0.81 | DNM1 (0.42) | CA2CA1DNM1FDPS | |
| SCHEMBL8372141 | 0.79 | TSHR (0.39) | TSHRSMN1; SMN2CA2MAPK1CA1 | |
| SCHEMBL2352763 | 0.79 | DNM1 (0.46) | TSHRCA2DNM1FDPS | |
| SCHEMBL2346103 | 0.79 | DNM1 (0.46) | TSHRCA2DNM1FDPS | |
| SCHEMBL2346107 | 0.79 | DNM1 (0.46) | TSHRCA2DNM1FDPS | |
| SCHEMBL8372167 | 0.78 | TSHR (0.42) | TSHRSMN1; SMN2CA2MAPK1CA1 | |
| SCHEMBL2349516 | 0.78 | DNM1 (0.38) | TSHRSMN1; SMN2CA2MAPK1CA1 | |
| SCHEMBL2346645 | 0.78 | TSHR (0.42) | TSHRSMN1; SMN2CA2MAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070264235-A1 | Polypeptide Having an Improved Cytosine Deaminase Activity | TRANSGENE S.A. (FR) | 2007-11-15 | — | — | US | disclosed |
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | GIFU UNIVERSITY (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | NSUN2, RNMT, RNGTT | TSHR 2330/4885SMN1; SMN2 84/4885CA2 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.